Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesSmall cell cancer of the bladder: pathology, diagnosis, treatment and prognosis
Bulletin du Cancer, 06/29/09
Ismaili N et al. - The most common staging system used is the two-stage system (limited-extensive). Because of the rarity of the disease, the management is extrapolated from that of SCLC. Limited-stage disease should be treated with etoposide-cisplatin chemotherapy in combination either with radiotherapy, or surgery or both. Extensive-stage disease should be managed by combined chemotherapy.
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09
Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09
Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Article Search
Sponsor